findmyKOL
Clinical trialNCT01695590UnknownPhase 1/PHASE2Interventional

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

SponsorProlexys PharmaceuticalsEnrollment40Multiple Myeloma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for patients with relapsed or relapsed/refractory multiple myeloma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Robert Schlossman, MD
    Recruiting
  • Tufts Medical Center

    Boston, Massachusetts, United States

    Withdrawn
  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, United States

    Peter Voorhees, MD
    Recruiting
  • Duke University Medical Center

    Durham, North Carolina, United States

    Cristina Gasparetto, MD
    Recruiting
  • University of Cincinnati

    Cincinnati, Ohio, United States

    John Morris, MD
    Recruiting
  • Sarah Cannon Research Institute

    Nashville, Tennessee, United States

    Jesus G. Berdeja, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

3-(2-Ethoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4-one
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2012
Primary completion
31 Mar 2014
Completion
30 Sept 2014
Last update posted
4 Jun 2013
Registered enrollment
40
Registry id
NCT01695590
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.